[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368370-105":59,"doc-detail-368370-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genetically-druggable-targets-for-mapk-activated-colorectal-cancer-by-a-two-sample-mendelian-randomization-analysis","Genetically druggable targets for MAPK-activated colorectal cancer by a two-sample mendelian randomization analysis","","Colorectal cancer (CRC) remains a major global cause of morbidity and mortality, with MAPK-activated signal pathways and RAS/BRAF-driven oncogenic activation contributing to resistance and limited therapeutic options. This study uses two-sample Mendelian randomization with plasma protein quantitative trait loci (pQTL) to test causal associations with MAPK-activated CRC. Four plasma proteins—MICB, complement C4A, C4B, and IL-21—associate with increased CRC risk, supporting plasma proteins as potential druggable targets and diagnostic biomarkers. Further research is needed to validate and expand these findings.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genetically-druggable-targets-for-mapk-activated-colorectal-cancer-by-a-two-sample-mendelian-randomization-analysis/368370/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genetically-druggable-targets-for-mapk-activated-colorectal-cancer-by-a-two-sample-mendelian-randomization-analysis/368370.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What method does the study use to assess plasma proteins and MAPK-activated CRC?","Question",{"text":112,"@type":113},"It applies two-sample Mendelian randomization using plasma protein quantitative trait loci (pQTL) to evaluate causal associations with MAPK-activated colorectal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which plasma proteins are linked to higher risk of MAPK-activated colorectal cancer?",{"text":117,"@type":113},"MICB (MHC class I polypeptide-related sequence B), complement C4A, complement C4B, and interleukin-21 (IL-21) are associated with increased risk.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are MAPK-activated CRCs described as difficult to treat?",{"text":121,"@type":113},"RAS and BRAF mutations drive persistent MAPK pathway activation and are linked to resistance to anti-EGFR therapies, contributing to limited treatment options and generally poor outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368370,1790472722,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nGenetically druggable targets for MAPK-activated colorectal cancer by a two-sample mendelian randomization analysis  \nYuxuan Zhou1, Yunlong Ding2, Bangyue Xu3, Hongyang Fei4 & Zheng Wang1􀀍  \nColorectal cancer (CRC) is a significant worldwide health issue, ranking second in women and third in men. Predictions estimate a rise to 2.5 million cases by 2035, with CRC being the fourth deadliest cancer due to delayed diagnosis and the scarcity of effective treatment options. Over 60% ofCRC cases involve MAPK-activated signal pathways, particularly driven by RAS oncogene mutations, which hinder treatment responses, making them ‘undruggable.’ This study conducts a two-sample Mendelian randomization protein quantitative trait loci (pQTL) analysis to investigate the causal association between plasma proteins and MAPK-activated CRCs. The study indicates that four plasma proteins—MHC class I polypeptide-related sequence B (MICB), complement C4A, C4B, and interleukin-21 (IL-21) are associated with an increased risk of MAPK-activated CRCs. These findings highlight the possibility of utilizing plasma proteins as therapeutic targets and diagnostic markers to advance the fight against CRCs, indicating promising results for more effective interventions. To ascertain and expand upon these discoveries, further research is imperative to fully harness the potential of these discoveries.  \nColorectal cancer (CRC) is a pervasive form of cancer, ranking second among women and third among men in global prevalence. The incidence of CRC is on the rise, with an expected surge to 2.5 million new cases by 20351. This cancer is also a leading cause of mortality, claiming nearly 900,000 lives each year, largely due to late detection and limited treatment options2.  \nThe Mitogen-activated protein kinases (MAPK) signaling pathway plays a crucial role in regulating cellular proliferation and differentiation, with its dysregulation closely linked to the etiology, progression, and malignant behavior of CRC3. RAS gene mutations, which are present in about half of all CRC cases, are a major cause of the persistent activation of the MAPK pathway4. The RAS protein family includes HRAS, NRAS, and two KRAS variants (4 A and 4B)5, with KRAS mutations being the most prevalent, accounting for 40–50% of RAS-mutant CRCs6.  \nBeyond RAS, BRAF mutations, particularly the BRAF V600E variant, also contribute to the activation of the MAPK pathway via downstream MEK and ERK7. As a key component in the RAS-RAF-MEK-ERK signaling cascade, BRAF mutations are significant, occurring in about 10% of cases8.  \nRAS and BRAF mutations are generally recognized as a negative prognostic factor. Patients with these mutations often show resistance to anti-EGFR therapies, leaving them with limited treatment options and generally poor outcomes9, 10. Consequently, cancers with these mutations are still challenging to treat and are sometimes referred to as ‘undruggable’11. These mutations have profound effects on tumor development. KRAS mutations, for instance, can accelerate tumor progression and cell proliferation, typically emerging early in the disease’s course. NRAS mutations may hinder the cell’s ability to undergo stress-induced death12. Therefore, identifying potential biomarkers for treating MAPK-activated colorectal cancer and monitoring its progression is of utmost importance.  \nNowadays, plasma proteins have emerged as promising indicators for a variety of diseases and are considered valuable therapeutic targets13. The majority of drugs approved by the FDA in 2017 were designed to target human proteins14. In CRC, targeting specific plasma proteins, such as complement C4B, has shown potential in inhibiting cell proliferation and enhancing tumor cell apoptosis15.  \n1Department of Gastrointestinal Surgery/Hernia Surgery, Jilin Province People’s Hospital, No. 1183 Gongnong Road, Changchun, Jilin, China. 2Department","cbCaim2PvquLgAiC","https://ap.wps.com/l/cbCaim2PvquLgAiC","pdf",2140599,11,"English","# Background\n## Epidemiology of colorectal cancer\n## MAPK pathway and RAS/BRAF mutations\n## Need for biomarkers and “undruggable” targets\n# Rationale for plasma proteins and MR\n## Plasma proteins as therapeutic and diagnostic candidates\n## Mendelian randomization for causal inference\n# Study approach\n## Two-sample MR design for MAPK-activated CRC","[{\"question\":\"What method does the study use to assess plasma proteins and MAPK-activated CRC?\",\"answer\":\"It applies two-sample Mendelian randomization using plasma protein quantitative trait loci (pQTL) to evaluate causal associations with MAPK-activated colorectal cancer.\"},{\"question\":\"Which plasma proteins are linked to higher risk of MAPK-activated colorectal cancer?\",\"answer\":\"MICB (MHC class I polypeptide-related sequence B), complement C4A, complement C4B, and interleukin-21 (IL-21) are associated with increased risk.\"},{\"question\":\"Why are MAPK-activated CRCs described as difficult to treat?\",\"answer\":\"RAS and BRAF mutations drive persistent MAPK pathway activation and are linked to resistance to anti-EGFR therapies, contributing to limited treatment options and generally poor outcomes.\"}]","Genetically druggable targets for MAPK-activated colorectal cancer by a two-sample mendelian randomization analysis | PDF",1790176580,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdd16c2a76912d811ba3868eeec1147f.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c94abbcd7f545eb322df3c99456f3ba6.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a29e46a301f0383a11ee2fbc1eb3db4b.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78dd7aa8a76c897b8b66a2b297ea22ab.webp",980,1287]